{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-126317","form_type":"8-K","ticker":"MGX","cik":"0001785279","company_name":"Metagenomi Therapeutics, Inc.","filed_at":"2024-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.620310+00:00","generated_at":"2026-05-30T01:01:06.138399+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Metagenomi nominates MGX-001 DC for hemophilia A; reports $274.6M cash; Q3 expenses down","bullets":["Nominated MGX-001 as first development candidate for hemophilia A; IND-enabling activities initiated, IND filing on track for 2026.","Cash, cash equivalents and marketable securities $274.6M at Sept 30, 2024; cash runway expected into 2027.","R&D expenses $26.3M in Q3 2024 (vs $26.8M Q3 2023); G&A $7.6M (vs $7.9M).","Ionis collaboration: all four wave 1 programs in lead optimization; one to two DC nominations expected in 2025.","Novel ABE platform targets >95% of genome base pairs; SMART platform enables single-AAV delivery for neuromuscular."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-126317","json":"https://secwatch.observer/filing/0000950170-24-126317.json","markdown":"https://secwatch.observer/filing/0000950170-24-126317.md","text":"https://secwatch.observer/filing/0000950170-24-126317.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1785279/000095017024126317/0000950170-24-126317-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1785279/000095017024126317/mgx-20241113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T01:01:06.138399+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}